Design Therapeutics (DSGN) Stock Forecast, Price Target & Predictions
DSGN Stock Forecast
Design Therapeutics stock forecast is as follows: an average price target of $9.67 (represents a 74.55% upside from DSGN’s last price of $5.54) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
DSGN Price Target
The average price target for Design Therapeutics (DSGN) is $9.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $7.00. This represents a potential 74.55% upside from DSGN's last price of $5.54.
DSGN Analyst Ratings
According to 2 Wall Street analysts, Design Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DSGN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Design Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 07, 2024 | Yasmeen Rahimi | Piper Sandler | $12.00 | $3.65 | 228.77% | 116.61% |
| Aug 15, 2023 | Leonid Timashev | RBC Capital | $7.00 | $2.17 | 223.33% | 26.35% |
| Dec 07, 2022 | Yasmeen Rahimi | Piper Sandler | $42.00 | $12.69 | 230.97% | 658.12% |
| May 02, 2022 | - | RBC Capital | $30.00 | $11.94 | 151.26% | 441.52% |
| Jan 19, 2022 | Madhu Kumar | Goldman Sachs | $10.00 | $13.98 | -28.47% | 80.51% |
The latest Design Therapeutics stock forecast, released on May 07, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $12.00, which represents a 228.77% increase from the stock price at the time of the forecast ($3.65), and a 116.61% increase from DSGN last price ($5.54).
Design Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $5.54 | $5.54 | $5.54 |
| Upside/Downside | -100.00% | -100.00% | 116.61% |
In the current month, the average price target of Design Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Design Therapeutics's last price of $5.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2023 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Dec 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 02, 2022 | RBC Capital | - | Outperform | Initialise |
| Jan 19, 2022 | Goldman Sachs | - | Cautious | Initialise |
Design Therapeutics's last stock rating was published by RBC Capital on Aug 15, 2023. The company Downgrade its DSGN rating from "Outperform" to "Sector Perform".
Design Therapeutics Financial Forecast
Design Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Design Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DSGN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Design Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict DSGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Design Therapeutics's previous annual EBITDA (undefined) of $NaN.
Design Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-16.68M | $-16.12M | $-15.84M | $-15.84M | $-14.70M | $-13.76M | $-13.20M |
| High Forecast | $-16.68M | $-16.12M | $-15.84M | $-15.84M | $-14.70M | $-12.17M | $-13.20M |
| Low Forecast | $-16.68M | $-16.12M | $-15.84M | $-15.84M | $-14.70M | $-15.35M | $-13.20M |
| Surprise % | - | - | - | - | - | - | - |
Design Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DSGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Design Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Design Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DSGN last annual SG&A of $NaN (undefined).
Design Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.28 | $-0.26 | $-0.24 | $-0.23 |
| High Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.28 | $-0.26 | $-0.22 | $-0.23 |
| Low Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.28 | $-0.26 | $-0.27 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Design Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DSGN previous annual EPS of $NaN (undefined).
Design Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALVR | AlloVir | $0.75 | $34.00 | 4433.33% | Buy |
| ALXO | ALX Oncology | $2.22 | $24.50 | 1003.60% | Buy |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| ADCT | ADC Therapeutics SA | $3.10 | $9.33 | 200.97% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| IMCR | Immunocore | $33.55 | $75.50 | 125.04% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| AADI | Aadi Bioscience | $1.80 | $1.63 | -9.44% | Hold |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
DSGN Forecast FAQ
Is Design Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Design Therapeutics (DSGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of DSGN's total ratings.
What is DSGN's price target?
Design Therapeutics (DSGN) average price target is $9.67 with a range of $7 to $12, implying a 74.55% from its last price of $5.54. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Design Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DSGN stock, the company can go up by 74.55% (from the last price of $5.54 to the average price target of $9.67), up by 116.61% based on the highest stock price target, and up by 26.35% based on the lowest stock price target.
Can Design Therapeutics stock reach $8?
DSGN's average twelve months analyst stock price target of $9.67 supports the claim that Design Therapeutics can reach $8 in the near future.
What are Design Therapeutics's analysts' financial forecasts?
Design Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-41.663M (high $-40.074M, low $-43.251M), average SG&A $0 (high $0, low $0), and average EPS is $-0.737 (high $-0.709, low $-0.765). DSGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.474M (high $-64.474M, low $-64.474M), average SG&A $0 (high $0, low $0), and average EPS is $-1.14 (high $-1.14, low $-1.14).